ARCHIVES

In Brief: Calabresi: Rimer: Outstanding ”For NCAB Chair; board Should Maintain Strong Leadership Role

This article is from The Cancer Letter archive.

Vol. 20 No. 36 | September 23, 1994

Download PDF Visit The Full Archive

Related Articles

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

July 13, 2007

In Brief: Trials Find DiBella Treatment Ineffective; Wistar Wins $1 Million Grant For Recruitment

December 4, 1998

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

ASCO Honors Holland, Koop, Monaco With Special Awards

June 11, 1993

Low-Dose IFN Not Effective Against Melanoma, Study Finds

December 26, 2003

Lung Cancer Size May Not Indicate Severity Of Disease

March 29, 2002